Literature DB >> 12009007

Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.

Katsuhiro Ono1, Takuhiko Akatsu, Takehiko Murakami, Ryuichi Kitamura, Michiko Yamamoto, Nariyoshi Shinomiya, Makoto Rokutanda, Tomoyo Sasaki, Norio Amizuka, Hidehiro Ozawa, Naokazu Nagata, Nobuo Kugai.   

Abstract

We previously reported that mouse mammary carcinoma cell lines (MMT060562 and BALB/c-MC) induced osteoclast formation through production of prostaglandin E2 (PGE2) in cocultures with mouse bone marrow cells, but the mechanism(s) of PG production remained unclear. In the present in vitro and in vivo studies, we tested the involvement of cyclo-oxygenase-2 (COX-2), an inducible rate-limiting enzyme in PG biosynthesis, in the stimulation of osteoclast formation by mouse mammary carcinoma cell lines. Addition of a selective COX-2 inhibitor, JTE-522, to cocultures of mammary carcinoma cell lines and bone marrow cells lowered PGE2 concentration in the culture media and inhibited osteoclast formation in a dose-dependent manner. Northern blotting showed a very high level of COX-2 messenger RNA (mRNA) expression in MMT060562. The mRNA expression was low in BALB/c-MC, but it increased when BALB/c-MC and bone marrow cells were cocultured. The results of immunocytochemistry for COX-2 protein in respective cultures were compatible with the results of COX-2 mRNA. In vivo, BALB/c-MC injected into the heart of Balb/c mice metastasized to bone and formed osteolytic lesions in their hindlimbs. Histological examination revealed that tumor cells had metastasized to the bone marrow cavity and destroyed the bone trabeculae. Immunohistochemistry demonstrated that bone marrow stromal cells adjacent to tumor cells expressed COX-2 protein. These findings suggest that COX-2 plays an important role in the osteolysis of bone metastasis in vivo as well as in osteoclast formation in cocultures used as an in vitro model of metastatic bone disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009007     DOI: 10.1359/jbmr.2002.17.5.774

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

1.  CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.

Authors:  Fei Liu; Sun-Kyeong Lee; Douglas J Adams; Gloria A Gronowicz; Barbara E Kream
Journal:  Bone       Date:  2007-02-01       Impact factor: 4.398

2.  Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Authors:  Zahida Qamri; Anju Preet; Mohd W Nasser; Caroline E Bass; Gustavo Leone; Sanford H Barsky; Ramesh K Ganju
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

3.  A role for leukemia inhibitory factor in melanoma-induced bone metastasis.

Authors:  Shigeaki Maruta; Soichi Takiguchi; Miho Ueyama; Yasufumi Kataoka; Yoshinao Oda; Masazumi Tsuneyoshi; Haruo Iguchi
Journal:  Clin Exp Metastasis       Date:  2008-10-25       Impact factor: 5.150

4.  Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis.

Authors:  Zhigang Li; Christian Schem; Yihui H Shi; Daniel Medina; Ming Zhang
Journal:  Clin Exp Metastasis       Date:  2007-10-27       Impact factor: 5.150

5.  Internal prostaglandin synthesis augments osteoprotegerin production in human gingival fibroblasts stimulated by lipopolysaccharide.

Authors:  M Kiji; T Nagasawa; D Hormdee; R Yashiro; H Kobayashi; K Noguchi; H Nitta; Y Izumi; I Ishikawa
Journal:  Clin Exp Immunol       Date:  2007-06-05       Impact factor: 4.330

6.  Mitogen-activated Protein Kinase (MAPK) Activated by Prostaglandin E2 Phosphorylates Connexin 43 and Closes Osteocytic Hemichannels in Response to Continuous Flow Shear Stress.

Authors:  Manuel A Riquelme; Sirisha Burra; Rekha Kar; Paul D Lampe; Jean X Jiang
Journal:  J Biol Chem       Date:  2015-10-06       Impact factor: 5.157

Review 7.  COX-2 inhibitors for the prevention of breast cancer.

Authors:  Louise R Howe; Andrew J Dannenberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

Review 8.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

9.  COX2 confers bone marrow stromal cells to promoting TNFα/TNFR1β-mediated myeloma cell growth and adhesion.

Authors:  Chunmei Kuang; Yinghong Zhu; Yongjun Guan; Jiliang Xia; Jian Ouyang; Guizhu Liu; Mu Hao; Jiabin Liu; Jiaojiao Guo; Wenxia Zhang; Xiangling Feng; Xin Li; Jingyu Zhang; Xuan Wu; Hang Xu; Guancheng Li; Lu Xie; Songqing Fan; Lugui Qiu; Wen Zhou
Journal:  Cell Oncol (Dordr)       Date:  2021-03-01       Impact factor: 6.730

10.  Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.

Authors:  María Valcárcel; Lorea Mendoza; José-Julio Hernández; Teresa Carrascal; Clarisa Salado; Olatz Crende; Fernando Vidal-Vanaclocha
Journal:  J Transl Med       Date:  2011-08-25       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.